Keros Therapeutics (NASDAQ:KROS) Shares Gap Up – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS) gapped up prior to trading on Thursday . The stock had previously closed at $10.33, but opened at $11.67. Keros Therapeutics shares last traded at $12.40, with a volume of 3,289,143 shares.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on KROS. Scotiabank decreased their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Oppenheimer lowered their price objective on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.33.

Keros Therapeutics Trading Down 0.5 %

The stock has a fifty day moving average of $10.91 and a two-hundred day moving average of $30.80. The company has a market capitalization of $494.05 million, a PE ratio of -2.34 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. Equities analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its position in Keros Therapeutics by 6.8% during the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after acquiring an additional 46,041 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Keros Therapeutics in the fourth quarter worth approximately $388,000. Barclays PLC grew its holdings in shares of Keros Therapeutics by 140.1% in the third quarter. Barclays PLC now owns 60,014 shares of the company’s stock worth $3,484,000 after purchasing an additional 35,022 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Keros Therapeutics in the fourth quarter worth $461,000. Finally, American Century Companies Inc. raised its holdings in Keros Therapeutics by 10.5% during the 4th quarter. American Century Companies Inc. now owns 328,920 shares of the company’s stock valued at $5,207,000 after buying an additional 31,251 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.